Article
Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
Current drug metabolism - 1 May 2007
Secchiero Paola, Zerbinati Carlotta, di Iasio Maria Grazia, Melloni Elisabetta, Tiribelli Mario, Grill Vittorio, Zauli Giorgio
Abstract excerpt
To potentiate the response of acute myeloid leukemia (AML) to TRAIL cytotoxicity, we have adopted a strategy of combining nutlin-3, a potent non-genotoxic activator of the p53 pathway, with recombinant TRAIL. The rationale for using such a combination was that deletions and/or mutations of the p53 gene occur in only 5-10% of AML and that TRAIL and nutlin-3 activate the extrinsic and intrinsic pathways of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.